Next Phase Newsletter

A venture capital firm founded in 2012 with $300M AUM is currently investing from its third fund. The firm focuses on early-stage investments from Seed to Series A, and initial size of investment can range from $500K to up to $3M. The firm reserves a significant part of the fund as follow-on investment. With the current fund, the firm seeks to invest in a total of 6-8 companies, with a preference for companies that are within proximity to their office in the Bay area.

The firm is interested in technologies that incorporate mobility and data. In terms of life sciences and healthcare, this includes digital health, AI and big data in discovery, precision medicine, etc. The firm has made several investments in digital health companies – examples include a mobile coaching app that promotes smarter decisions and better outcomes, a digital health platform for chronic disease management, etc.

The firm looks for driven management teams – relevant industry experience is a definite plus, but not an absolute requirement. The firm works closely with portfolio companies, providing companies with the needed resources and expertise to achieve scalability. The firm prefers to act as the lead investor, typically taking a board seat in such cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A single family office based in the USA with a team of particularly strong expertise in building and growing biotechnology and pharmaceutical companies invests broadly in healthcare and is open to companies of all stages. The size of investment can largely vary depending on the stage of the company. The firm has invested mainly in USA-based companies but is open to global opportunities.

The firm has a broad interest in healthcare and is most interested in private biotech companies, with a few investments in medical device companies as well. Within therapeutics, the firm’s sweet spot is from pre-clinical to late-stage II, with particular interest in assets with accelerated or de-risked regulatory pathways. The firm is interested in all indications, including oncology and immunotherapies. The firm also considers gene therapy as an area of high interest. In terms of medical devices, the firm is most interested in minimally invasive devices and is open to 510k and PMA regulatory pathways.

The firm seeks to work with experienced management teams with strong scientific expertise. Another important consideration is other investors that have participated in the financing. The firm invests in both public and private companies and will most likely seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in China has over $4 billion in total managed assets in the areas of healthcare, technology and internet, and clean tech. The firm has invested in more than 70 healthcare companies that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services.

The firm closed their healthcare fund in early 2018, focused on early-stage health care opportunities in the US with potential market opportunities in China. The firm has USA operations in both the West and East Coast. The firm intends to lead, co-lead, or co-invest in US-based private companies in biotech for therapeutics, medtech, and digital health technologies, with equity investments ranging from $5 to $15 million. The firm will not make public company investments.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence,” The firm’s team is “hands-on” and typically assumes a board seat after an investment. Investments in US companies are expected to have upside opportunities in China and can leverage the firm’s China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 and with offices in the West Coast is actively investing in Seed to Series A rounds. In addition to providing equity capital, the firm will also assist companies with intellectual property. The firm is open to opportunities in North America (USA and Canada).

The firm is interested in early-stage medical technology, diagnostics, and digital health/wellness companies and is open to medical devices of all regulatory pathways including 510k and PMA. The firm strongly prefers products that have received FDA clearance but is open to working with pre-FDA products. The firm will generally not pursue opportunities in biopharma therapeutics.

The firm seeks to work with privately owned companies that are backed by an experienced management team. The firm likes to form syndicates and prefers co-investing in financing rounds, but the firm can lead rounds as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2016 focused on cross-border investments. When investing, the firm doesn’t only provide financial capital, they also provide their global consulting services focused specifically on helping companies work across borders and in China. Currently, the firm is partnered with the Chinese Government to bring promising projects from North America to China and are focused on technologies that are at an advanced stage with patents that are willing to launch in Chinese markets or to set up factories and labs in China. The firm is however, willing to invest smaller amounts in good opportunities that have no interest/fit for the Chinese markets as well. The firm’s major focus within the life sciences is biotech and is focused on seed to series B rounds. The firm generally invests up to $10M USD for Series A deals, is flexible for series B rounds, and invests up to $1M USD for seed stage rounds.

Within the Life Sciences space, the firm is specifically focused on clinical tests, therapeutics, and other biotech technologies. The firm is also interested in medical devices focusing on large disease areas within China such as diabetes and cancer. Additionally, the firm is focused on technologies within these sectors that have a good fit with the Chinese Market or have a strong interest in working in China.

When investing, the firm looks to take a board seat. The firm provides consulting, localization services, and the ability to leverage resources in China to help the company grow alongside their direct equity investment and believe that these abilities can be best leveraged with a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA manages 5 funds for with its most recently fund having had its first close in 2017. The firm looks to provide up to $3-4 million of preferred equity capital in the initial round and up to $6 million over the life of the investment. The firm is very flexible in terms of period to exit but generally looks to exit in around 5 years. The firm will consider companies globally.

The firm is currently looking for companies developing Therapeutics and Medical Technology. Within therapeutics which is the firms primary focus, companies with an asset anywhere from preclinical with positive animal data to Phase II will be considered. The firm is generally open to all technology types and indications with the exception of wound care and psychiatry. Within devices, the firm is currently looking for market approved product with early revenue; however, devices are not an investment priority at present. The firm is looking for companies targeting true un-met medical needs where either no treatment currently exists or the existing standard of care is wrought with side-effects and other impediments to quality care.

The firm does not have any specific requirement for a firm’s management team although they are an active investor looking to take a seat on the company’s board. The firm -generally tends to lead or co-lead investments into selected companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A pharmaceutical company based in Seoul with annual sales of about $140 million with more than 600 employees has several clinical pipelines under global phase II in the area of CNS and diabetes, CNS clinical pipeline under phase III in Korea, and a late preclinical stage oncology product as well as an early preclinical candidates targeting TEC kinase family developed in-house.

The firm’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.